Veritas is an extremely conformable and strong biomaterial which acts as a 'scaffold' that allows for rapid repopulation and revascularization by the surrounding host tissue, said Synovis.
In addition to providing strength and flexibility, Veritas avoids acute and chronic infections and unwanted chronic inflammation that occurs frequently in response to the use of synthetic patches, claims Synovis. The distinct characteristics of Veritas, which include its pericardial substrate and proprietary processing, offer functional and ease of use advantages over other biological patches, the company added.
Richard Kramp, president and CEO of Synovis, said: "The CE Mark approval for these indications is a significant milestone for Veritas. With the addition of the European market for hernia repair and breast reconstruction, we look forward to expanding our presence in the worldwide soft tissue repair market and increasing our international revenue.
"We have already trained our independent distributors in Europe on the advantages of Veritas, and they will immediately start to sell Veritas to the European physician community. The hernia repair and breast reconstruction applications represent large and strong European market opportunities for Synovis."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index